SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
Source: SeekingAlpha
2025-02-20 10:48:10 ET
More on SELLAS Life Sciences
- SELLAS Life Sciences falls after data for blood cancer therapy
- SELLAS reports positive survival data from mid-stage trial of its leukemia treatment
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Historical earnings data for SELLAS Life Sciences
- Financial information for SELLAS Life Sciences
Read the full article on Seeking Alpha
For further details see:
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group Inc.
NASDAQ: SLS
SLS Trading
1.87% G/L:
$7.10 Last:
2,020,090 Volume:
$7.16 Open:
SLS Latest News
May 12, 2026 04:05:00 pm
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMarch 19, 2026 04:05:00 pm
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate UpdateSLS Stock Data
$535,597,063
140,448,048
1.12%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
